Yunnan Baiyao
Yunnan Baiyao
Yunnan Baiyao Group manufactures and sells traditional Chinese medicine and preparations, personal care products, and native herbs.
Yunnan Baiyao, founded in November, 1993 and headquartered in Kunming, is a pharmaceutical and health enterprise. The founder is Chen Fashu. Listed on the SZSE on December 15, 1993, the company's major shareholders are Yunnan State-owned Assets Supervision and Administration Commission, Xinhuadu Industrial Group Co., Ltd., Jiangsu Yuyue Technology Development Co., Ltd.. Rivals that have direct and indirect competition with Yunnan Baiyao include Harbin Pharmaceutical, Tongrentang, Glaxo Smith Kline, Pfizer, etc.
- All
- News
- Analysis
- Research
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
In-depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing May 18, 2022 04:45 PM
Taier shares: the contract dispute case against Cao Linbin was accepted by the court
In-depth
Healthcare
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Yesterday 02:13 PM
Healthcare
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Briefing Oct 30, 2021 07:57 AM
· Healthcare
Economic Daily: enterprise investment should not abandon the main business
In-depth
Healthcare
Yunnan Baiyao: An Oriental Mystery in the Limelight (2/2)
Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.
May 19, 2020 12:30 PM
In-depth
Healthcare
Yunnan Baiyao: An Oriental Mystery in the Limelight (1/2)
Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.
May 19, 2020 12:00 PM
Briefing Oct 28, 2021 03:23 PM
· Healthcare
Yunnan Baiyao responded that it lost 1.5 billion in stock speculation: it will gradually optimize the structure and gradually withdraw from securities investment
Briefing Oct 27, 2021 04:38 PM
· Healthcare
Wanyi Technology: the net profit in the first three quarters increased by 286.04% to 5.2454 million yuan
Briefing Aug 30, 2021 08:46 AM
· Healthcare
August 30 stock market lightning rod
Briefing Jul 07, 2021 03:24 PM
· Healthcare
The first bank of China fund to release its second Quarterly Report
See more
Related Companies
